FDA Accepts Cogent Biosciences NDA for Bezuclastinib as Novo Nordisk Rebrands Amid Lilly Competition

Cogent Biosciences secured a key regulatory milestone as the FDA accepted its New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis, assigning a PDUFA target action date of December 30, 2026. The NDA was submitted under the FDA's Real-Time Oncology Review program, designed to streamline the review process, and bezuclastinib had previously received Breakthrough Therapy Designation for treating gastrointestinal stromal tumors. The company is building an internal commercial organization with plans to launch commercially in the United States in the second half of 2026 pending approval.

Novo Nordisk announced a strategic cultural reset, adopting the shortened day-to-day name "Novo" and unveiling a new framework called "The Novo Way" built around customer obsession, competitiveness, clarity, and care and integrity. The move comes as the Danish drugmaker faces mounting pressure from Eli Lilly's rapid market share gains in the obesity and diabetes market, alongside a significant pricing reset on Ozempic and Wegovy agreed with the U.S. administration and a planned workforce reduction of approximately 9,000 employees targeting annualized savings of around DKK 8 billion.

Shares of BlossomHill Therapeutics rose 4.4% in premarket trading after the company reported new trial data for its lung cancer drug candidate. Nuvation Bio presented new subgroup analyses at the 2026 World Conference on Lung Cancer reinforcing the durable and consistent efficacy of its approved ROS1-positive non-small cell lung cancer drug IBTROZI, known generically as taletrectinib, across key patient subgroups. Thryv Therapeutics announced the publication in JACC: Heart Failure of converging human genetic, preclinical, and clinical evidence supporting Phase 2a development of its lead SGK1 inhibitor THRV-1268 in heart failure.

The week also brought a wave of company presentations at major industry gatherings including the Morgan Stanley Global Healthcare Conference, the H.C. Wainwright conference, and the 2026 Global Healthcare Conference, where Claritev, PTC Therapeutics, Cardinal Health, REGENXBIO, Prime Medicine, Maze Therapeutics, Mirum Pharmaceuticals, and Candel Therapeutics outlined pipeline progress, growth strategies, and cash runway.